249 related articles for article (PubMed ID: 37377956)
21. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
22. epiTCR: a highly sensitive predictor for TCR-peptide binding.
Pham MN; Nguyen TN; Tran LS; Nguyen QB; Nguyen TH; Pham TMQ; Nguyen HN; Giang H; Phan MD; Nguyen V
Bioinformatics; 2023 May; 39(5):. PubMed ID: 37094220
[TBL] [Abstract][Full Text] [Related]
23. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
Elife; 2020 Apr; 9():. PubMed ID: 32314731
[TBL] [Abstract][Full Text] [Related]
24. A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy.
Wang X; Wong LM; McElvain ME; Martire S; Lee WH; Li CZ; Fisher FA; Maheshwari RL; Wu ML; Imun MC; Murad R; Toledo Warshaviak D; Yin J; Kamb A; Xu H
Toxicol Appl Pharmacol; 2022 Feb; 437():115894. PubMed ID: 35085592
[TBL] [Abstract][Full Text] [Related]
25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
26. NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.
Sommermeyer D; Conrad H; Krönig H; Gelfort H; Bernhard H; Uckert W
Int J Cancer; 2013 Mar; 132(6):1360-7. PubMed ID: 22907642
[TBL] [Abstract][Full Text] [Related]
27. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC; Border EC; Vieira JF; Pumphrey NJ
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy.
Sanderson JP; Crowley DJ; Wiedermann GE; Quinn LL; Crossland KL; Tunbridge HM; Cornforth TV; Barnes CS; Ahmed T; Howe K; Saini M; Abbott RJ; Anderson VE; Tavano B; Maroto M; Gerry AB
Oncoimmunology; 2020; 9(1):1682381. PubMed ID: 32002290
[TBL] [Abstract][Full Text] [Related]
29. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.
Soon CF; Behrendt P; Todt D; Manns MP; Wedemeyer H; Sällberg Chen M; Cornberg M
J Hepatol; 2019 Oct; 71(4):673-684. PubMed ID: 31203151
[TBL] [Abstract][Full Text] [Related]
30. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
31. Tuning T cell receptor sensitivity through catch bond engineering.
Zhao X; Kolawole EM; Chan W; Feng Y; Yang X; Gee MH; Jude KM; Sibener LV; Fordyce PM; Germain RN; Evavold BD; Garcia KC
Science; 2022 Apr; 376(6589):eabl5282. PubMed ID: 35389803
[TBL] [Abstract][Full Text] [Related]
32. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
Wargo JA; Robbins PF; Li Y; Zhao Y; El-Gamil M; Caragacianu D; Zheng Z; Hong JA; Downey S; Schrump DS; Rosenberg SA; Morgan RA
Cancer Immunol Immunother; 2009 Mar; 58(3):383-94. PubMed ID: 18677478
[TBL] [Abstract][Full Text] [Related]
33. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
34. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
[TBL] [Abstract][Full Text] [Related]
35. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
36. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
37. High-Throughput Screening of Functional Neo-Antigens and Their Specific T-Cell Receptors via the Jurkat Reporter System Combined with Droplet Microfluidics.
Li Y; Qi J; Liu Y; Zheng Y; Zhu H; Zang Y; Guan X; Xie S; Zhao H; Fu Y; Xiang H; Zhang W; Chen H; Liu H; Zhao Y; Feng Y; Bu F; Liang Y; Li Y; Xu Q; He Y; Sun L; Liu L; Gu Y; Xu X; Hou Y; Dong X; Liu Y
Anal Chem; 2023 Jun; 95(25):9697-9705. PubMed ID: 37300490
[TBL] [Abstract][Full Text] [Related]
38. The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy.
Arman I; Haus-Cohen M; Reiter Y
Cells; 2022 Dec; 12(1):. PubMed ID: 36611821
[TBL] [Abstract][Full Text] [Related]
39. Identification of NY-ESO-1
Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
Front Immunol; 2021; 12():644520. PubMed ID: 33833762
[TBL] [Abstract][Full Text] [Related]
40. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
